Press Releases

Date Title and Summary View
Jan 25, 2021
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb)   showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® ( trastuzumab), both with chemotherapy In the U.S. , MARGENZA is approved, in combination with chemotherapy, for the treatment of
Jan 11, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Jan. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc.  (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate
Dec 22, 2020
MacroGenics Announces MGD019 Publication in Cell Reports Medicine
PD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escalation clinical study ROCKVILLE, MD , Dec. 22, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc.  (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based
Dec 18, 2020
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
ROCKVILLE, MD , Dec. 18, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license
Dec 16, 2020
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with chemotherapy, for the treatment of
Dec 07, 2020
MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting
53.8% ORR in relapsed/refractory DLBCL patients  Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date  ROCKVILLE, MD , Dec. 07, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company
Dec 06, 2020
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patients Median duration of response = 8.13 months ROCKVILLE, MD , Dec. 06, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing
Nov 30, 2020
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expenses EVERSANA may earn revenue share payments over five years subject to predefined cap MacroGenics’ projected cash runway remains into 2023 ROCKVILLE, MD and CHICAGO, IL , Nov.
Nov 30, 2020
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
ROCKVILLE, MD , Nov. 30, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that $25 million in milestones have
Nov 09, 2020
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Nov. 09, 2020 (GLOBE NEWSWIRE) --   MacroGenics , Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Nov 04, 2020
MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Nov 04, 2020
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
ROCKVILLE, MD , Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced six clinical and preclinical abstracts
Oct 28, 2020
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
ROCKVILLE, MD , Oct. 28, 2020 (GLOBE NEWSWIRE) --   MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Oct 15, 2020
MacroGenics Announces Flotetuzumab Publication in Blood Advances
— Role of TP53 abnormalities in immunotherapy response in AML highlighted ROCKVILLE, MD , Oct. 15, 2020 (GLOBE NEWSWIRE) --   MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the
Sep 23, 2020
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
Manuscript describes preclinical development of MGC018 Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD , Sept. 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical
Sep 22, 2020
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
ROCKVILLE, MD , Sept. 22, 2020 (GLOBE NEWSWIRE) --   MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in
Sep 21, 2020
MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD , Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based
Sep 20, 2020
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition Recommended Phase 2 dose established for MSS CRC, NSCLC expansion cohorts Presentation is available on-demand as part of the ESMO Virtual Congress 2020  ROCKVILLE, MD ,
Sep 03, 2020
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Sept. 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Aug 05, 2020
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Aug. 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Jul 30, 2020
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results
Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , July 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Jul 23, 2020
MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call
Rockville, MD , July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Jul 09, 2020
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
Rockville, MD , July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Lancet Oncology has published
Jun 22, 2020
MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting
Rockville, MD , June 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American
Jun 16, 2020
MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer
Rockville, MD , June 16, 2020 (GLOBE NEWSWIRE) -- Stephen Eck appointed Chief Medical Officer of MacroGenics MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of